Arcus Biosciences, Inc. (NYSE:RCUS) Stock Holdings Lessened by Profund Advisors LLC

Profund Advisors LLC cut its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 63.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,737 shares of the company’s stock after selling 34,693 shares during the quarter. Profund Advisors LLC’s holdings in Arcus Biosciences were worth $301,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of RCUS. GAMMA Investing LLC raised its holdings in shares of Arcus Biosciences by 51.6% during the first quarter. GAMMA Investing LLC now owns 2,427 shares of the company’s stock valued at $46,000 after acquiring an additional 826 shares during the period. Headlands Technologies LLC purchased a new position in Arcus Biosciences during the 1st quarter worth approximately $59,000. Innealta Capital LLC purchased a new position in Arcus Biosciences during the 2nd quarter worth approximately $66,000. Capstone Investment Advisors LLC acquired a new stake in Arcus Biosciences during the 4th quarter valued at $203,000. Finally, ProShare Advisors LLC lifted its holdings in shares of Arcus Biosciences by 7.4% in the first quarter. ProShare Advisors LLC now owns 10,846 shares of the company’s stock valued at $205,000 after purchasing an additional 746 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Arcus Biosciences Stock Up 0.1 %

Shares of RCUS opened at $15.41 on Friday. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -4.95 and a beta of 0.90. The company’s fifty day moving average is $16.10 and its 200-day moving average is $16.14. Arcus Biosciences, Inc. has a 12 month low of $12.95 and a 12 month high of $20.31.

Arcus Biosciences (NYSE:RCUS) last posted its earnings results on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, hitting the consensus estimate of ($1.02). Arcus Biosciences had a negative net margin of 100.81% and a negative return on equity of 42.86%. The firm had revenue of $39.00 million for the quarter, compared to the consensus estimate of $26.24 million. During the same period in the prior year, the business posted ($1.04) earnings per share. The business’s quarterly revenue was up 34.5% on a year-over-year basis. As a group, research analysts predict that Arcus Biosciences, Inc. will post -3.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on RCUS shares. Truist Financial dropped their price target on Arcus Biosciences from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, June 24th. Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Arcus Biosciences in a report on Friday, August 9th. Citigroup raised their price target on shares of Arcus Biosciences from $36.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, June 3rd. Evercore ISI upgraded shares of Arcus Biosciences to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Arcus Biosciences in a research note on Friday, August 9th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $35.71.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.